ChemicalBook Product Catalog API Antineoplastic agents Other antineoplastic Drugs Rilotumumab

Rilotumumab

Product NameRilotumumab
CAS872514-65-3
MF
MW0
EINECS
MOL FileMol File

Chemical Properties

form	Liquid
color	Colorless to light yellow

Usage And Synthesis

Description

Rilotumumab is an anti-HGF antibody that prevents ligand binding to MET and its activation.

Uses

Rilotumumab (AMG 102) is an anti-HGF (anti-hepatocyte growth factor) monoclonal antibody, inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research[1][2].

Clinical Use

A phase I/II trial of rilotumumab in combination with erlotinib was evaluated in previously treated NSCLC patients with metastatic disease. The results indicated a favorable safety profile and success in terms of disease control rate. A phase Ib/II trial of rilotumumab or ganitumab in combination with etoposide and carboplatin or cisplatin was evaluated in extensive-stage SCLC patients.

in vivo

Rilotumumab (intraperitoneal injection; 1.5 mg/kg; once two days; 11 d) treatment inhibits glioma cell growth in vivo^[2].

Animal Model:	6-8-week-old BALB/c nu/nu female mice subcutaneous injected with U87MG.vIII cells^[2]
Dosage:	1.5 mg/kg
Administration:	Intraperitoneal injection; 1.5 mg/kg; once two days; 11 days
Result:	Reduced U87MG.vIII xenograft growth (P=0.0002) compared with vehicle-treated xenografts (P=0.0001).

References

[1] Ryan CJ, et al. Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone. Clin Cancer Res. 2013 Jan 1;19(1):215-24. DOI:10.1158/1078-0432.CCR-12-2605
[2] Greenall SA, et al. EGFRvIII-mediated transactivation of receptor tyrosine kinases in glioma: mechanism and therapeutic implications. Oncogene. 2015 Oct 8;34(41):5277-87. DOI:10.1038/onc.2014.448

Rilotumumab Supplier

Rilotumumab manufacturers

Related Product Information

Send Inquriy